Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications
Key Highlights
- ➤HARMONY Cohort 2: FACE-Q satisfaction improved 42.4 points in 30 GLP-1 users
- ➤HALO interim: FACE-Q satisfaction improved 39.6 points by month three
- ➤HALO interim: 95.7% remained satisfied or very satisfied they looked like themselves
- ➤HARMONY Cohort 1: multimodal treatment improved FACE-Q satisfaction 42.0 points
- ➤Exosome serum significantly improved skin tone evenness and smoothness by week one
Expert Statements
Joely Kaufman-Janette, M.D., Board-certified dermatologist, Skin Research Institute, and study investigator
“Patients on GLP-1 medications are navigating real changes in how their face looks, and those changes can affect their self-image and how they engage with others. Having data specific to this population gives us a clearer starting point for setting expectations and building a treatment plan that reflects what they’re experiencing.”
Darin Messina, Ph.D., Senior vice president, head of aesthetics research and development, AbbVie
“Our research is designed around the patients we serve, and that includes people taking GLP-1 medications for weight management. Over time, their aesthetic concerns can change and may call for more than one treatment approach. The breadth of the Allergan Aesthetics portfolio lets us study our products in combination to generate evidence that helps providers make informed decisions about their potential use together in practice.”
Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications PR Newswire
– HARMONY IN DIVERSITY is the first study of combined neurotoxin and filler treatment in adults on glucagon-like peptide-1 (GLP-1) medications. In this Phase 4 cohort, participants reported statistically significant improvements in satisfaction with facial appearance and skin quality following a treatment regimen that also included skincare – Interim results from HALO, a Phase 4 study of hyaluronic acid (HA) injectables in adults on GLP-1 medications, showed high patient satisfaction, with 95.7% of participants satisfied or very satisfied that they still looked like themselves – The findings are part of a broad Allergan Aesthetics scientific program at ASDS 2026, advancing research across medical weight loss, multimodal treatment, neurotoxin innovation and skin quality
Get started
Create a free account to read the full story.